Show simple item record

dc.contributor.authorBarker, Claire L
dc.contributor.authorPrice, Gareth J
dc.contributor.authorLee, Lip W
dc.contributor.authorMcPartlin, Andrew J
dc.date.accessioned2022-08-01T09:07:02Z
dc.date.available2022-08-01T09:07:02Z
dc.date.issued2022en
dc.identifier.citationBarker CL, Price GJ, Lee LW, McPartlin A. Baseline MD Anderson Symptom Inventory Score is Strongly Associated With Patient-reported Acute and Late Toxicity Following (Chemo) Radiotherapy for Head and Neck Cancers. Clinical Oncology. Elsevier BV; 2022.en
dc.identifier.pmid35688777en
dc.identifier.doi10.1016/j.clon.2022.05.018en
dc.identifier.urihttp://hdl.handle.net/10541/625364
dc.description.abstractAims: Patient-reported outcomes measures (PROMs) are an increasingly recognised end point of radiotherapy studies. We hypothesised that the baseline PROMs score is the strongest predictor for acute and late scores after treatment. We assessed the strength of association of baseline MD Anderson Symptom Inventory (MDASI) scores, alongside other known factors for patient- or clinician-reported toxicity, with acute (6-week) and late (12-month) scores in head and neck cancer (HNC) patients following (chemo)radiotherapy. Materials and methods: This was a retrospective analysis of longitudinal MDASI scores for 247 patients receiving (chemo)radiotherapy for HNC via multivariable linear regression. The factors investigated were: baseline symptom score, age, sex, concurrent chemotherapy, disease stage, radiotherapy fractionation, prior definitive surgery and performance status. Patients with a baseline score >4 in any item were defined as symptomatic in that category. Results: Patients rated symptomatic for an MDASI item pre-treatment on average reported statistically (P < 0.0005) and clinically (>-1.5) significant reductions in scores 6 weeks and 12 months after (chemo)radiotherapy for all considered sub-items except taste, dryness of mouth and problems with teeth. Conversely patients asymptomatic at baseline reported a worsening of scores at both time points. Other investigated factors showed little association with changes in MDASI scores following treatment. Conclusions: Our data show that baseline MDASI scores are strongly associated with patient-reported toxicity 6 weeks and 12 months after (chemo)radiotherapy for HNC. Patients who are symptomatic at baseline can experience an early and durable benefit from treatment. This finding can inform discussions with patients before therapy and has implications for use of PROMs scores for the assessment of toxicity in randomised trials.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.clon.2022.05.018en
dc.titleBaseline MD Anderson symptom inventory score is strongly associated with patient-reported acute and late toxicity following (chemo) radiotherapy for head and neck cancersen
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalClinical Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record